To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, MI-63, and a clonal resistant cell line was generated.
| Inventor | Institute |
|---|---|
| John Lunec | Newcastle University |
| SKU: | 152839 |
|---|---|
| Product description: | To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, MI-63, and a clonal resistant cell line was generated. |
| Conditional: | No |
| Production details: | Resistant cell lines were established by exposing SJSA-1 cells to MI-63. Single cell derived colonies were isolated with cloning cylinders and the clonal population expanded in culture medium containing the MDM2/p53 antagonist refreshed weekly for 60 days. Stage 1 resistant clones were then further exposed to increased concentrations of MI-63 for 30 days to generate stage 2 resistant clones. |
| Cellosaurus ID: | CVCL_HG09 |
| Parental cell line: | SJSA-1 |
| Disease: | Cancer |
| Cat. #: | 152839 |
|---|---|
| Provenance and Ownership: | The S_M6R1 Cell Line is owned by Cancer Research UK. CancerTools supplies the S_M6R1 Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing S_M6R1 Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Apoptosis and autophagy; Cancer; Cell biology; Drug development; Genetics |
| Organism: | Human |
| Tissue: | Bone |
| Model: | Cancer Model |
| Cancer Types In Detail: | Multipotential sarcoma;Osteosarcoma |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Drummond et al. 2016. Oncotarget. :. PMID: 27323823. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.